The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
